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Highlights: 
 
The C3 domains of IgE are the most susceptible to thermally induced unfolding, 
determined by differential scanning fluorimetry. 
 
The C3 domains are responsible for the characteristically low melting temperature of 
IgE. 
 
The C3 domains exhibit the greatest intrinsic flexibility. 
 
The quaternary structural diversity of the C3 domains is compared across all (34) 
known structures using a simplified single parameter. 
 
Human IgE-Fc and Fc3-4 domain structures are determined at the highest resolutions 
yet reported (1.75Å and 2.0Å respectively). 
 
 
Keywords:   
 
Antibody; immunoglobulin E; glycosylation; domain flexibility; thermal unfolding; 
differential scanning fluorimetry. 
 
 
Abbreviations:   
 
Fc3-4, sub-fragment of IgE-Fc consisting of the dimer of C3 and C4 domains; 
DSF, differential scanning fluorimetry; 
GlcNAc, N-acetylglucosamine; 
Man, mannose 
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Abstract 
Immunoglobulin E (IgE) is the antibody that plays a central role in the mechanisms of 
allergic diseases such as asthma. Interactions with its receptors, FcRI on mast cells 
and CD23 on B cells, are mediated by the Fc region, a dimer of the C2, C3 and C4 
domains. A sub-fragment lacking the C2 domains, Fc3-4, also binds to both 
receptors, although receptor binding almost exclusively involves the C3 domains. 
This domain also contains the N-linked glycosylation site conserved in other isotypes. 
We report here the crystal structures of IgE-Fc and Fc3-4 at the highest resolutions 
yet determined, 1.75Å and 2.0Å respectively, revealing unprecedented detail 
regarding the carbohydrate and its interactions with protein domains. Analysis of the 
crystallographic B factors of these, together with all earlier IgE-Fc and Fc3-4 
structures, shows that the C3 domains exhibit the greatest intrinsic flexibility and 
quaternary structural variation within IgE-Fc. Intriguingly, both well-ordered 
carbohydrate and disordered polypeptide can be seen within the same C3 domains. A 
simplified method for comparing the quaternary structures of the C3 domains in free 
and receptor-bound IgE-Fc structures is presented, which clearly delineates the FcRI 
and CD23 bound states. Importantly, differential scanning fluorimetric analysis of 
IgE-Fc and Fc3-4 identifies C3 as the domain most susceptible to thermally-
induced unfolding, and responsible for the characteristically low melting temperature 
of IgE.  
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1. Introduction 
 
IgE plays a central role in the molecular and cellular mechanisms of allergy, and is a 
validated therapeutic target in the development of new approaches to treat allergic 
diseases such as asthma. It exerts its effects through its two principal receptors, FcRI 
on mast cells, basophils and antigen-presenting cells, and CD23/FcRII on B cells.  
The former mediates allergic hypersensitivity, the latter regulates IgE levels, and both 
contribute to allergen presentation to the immune system [1, 2]. 
 
IgE causes long term sensitisation of mast cells due to the uniquely slow off-rate for 
the antibody/receptor complex (koff  = 1.9 x 10
-4 
s
-1
), and this is reproduced with the 
IgE-Fc fragment containing the dimer of C2, C3 and C4 domains [3]. The FcRI 
binding site comprises two sub-sites, one on each C3 domain [4, 5], and although the 
C2 domains are not directly involved, they contribute to this slow off-rate since the 
Fc3-4 fragment, lacking these domains, has a somewhat faster off-rate (koff  = 3.2 x 
10
-3
s
-1
) [3]. The overall affinities of IgE-Fc and Fc3-4 for FcRI are, however, 
comparable and high (Ka ≈ 10
10
 M
-1
). The CD23 binding site lies principally within 
the C3 domain but with a small contribution from C4 [6]; the affinity of both IgE-
Fc and Fc3-4 for CD23 is lower (Ka ≈ 10
7
 M
-1
), with one binding site in each chain. 
The C3 domain is thus the critical domain for receptor binding.  
 
When expressed alone, and in contrast to C2 and C4, the C3 domain displays a 
poorly ordered, “molten globule” structure [7, 8, 9, 10]. However, this isolated 
domain binds, albeit with lower affinity, to sFcRI [11, 7], in the process becoming 
more ordered [8, 9]. This is also the domain to which N-linked carbohydrate is 
attached, at a site that is conserved across other immunoglobulin isotypes; in IgE the 
glycosylation is of the high-mannose type [12, 13, 14, 15]. 
 
There are now several crystal structures of both IgE-Fc and Fc3-4 alone and in 
complex with soluble IgE-binding extracellular domains of FcRI (sFcRI), CD23 
(sCD23) and various inhibitors. The first crystal structure was of Fc3-4 bound to 
sFcRI (1F6A) [4], and this was followed by that of the free Fc3-4 (1FP5) [16]. 
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5 
The structure of IgE-Fc revealed the organization of the C2 domains for the first 
time (1O0V) [17], and caused much surprise when they were observed bent back onto 
the Fc3-4 domains in an asymmetric manner. Three new crystal forms of Fc3-4 
were then determined (3H9Y, 3H9Z, 3HA0) [18], which revealed conformational 
flexibility between the structures. IgE-Fc bound to sFcRI (2Y7Q) was determined 
along with a higher resolution structure of the free IgE-Fc (2WQR) [5]. The structure 
of Fc3-4 with an engineered disulphide bond, trapping Fc3-4 in an artificially 
closed, non-receptor binding conformation was determined (4GT7) [19] and the 
structure of the same constrained form of Fc3-4 was determined bound by two 
DARPin (designed ankyrin repeat protein) molecules (4GRG) [20]. The structure of 
Fc3-4 bound to calcium-free sCD23 was then determined (4EZM) [6] and 
subsequently the calcium-bound structure was also solved (4GKO) [21], as well as 
another crystal form of Fc3-4 bound to sCD23 (4KI1) [22]. IgE-Fc bound by two 
anti-IgE Fabs (aFabs) (4J4P) [23] unexpectedly captured the Fc in a fully extended 
conformation. The crystal structure of Fc3-4 bound by the neutralizing antibody Fab 
MEDI4212 was also determined (5ANM) [24]. The complexes of two anti-IgE 
omalizumab Fabs bound to the artificially constrained Fc3-4 (5HYS) [25] and to the 
native IgE-Fc (5G64) [26] were recently reported. The structure of the asymmetric 
complex of IgE-Fc bound to a single sCD23 molecule was also recently solved 
(5LGK) [27]. 
 
In FcRI-bound structures, the C3 domains move apart into an “open” conformation 
to accommodate receptor binding, compared with the uncomplexed fragments. 
However, binding to CD23 between the C3 and C4 domains causes the C3 
domains to adopt a more “closed” conformation, and in this way the binding to the 
two receptors, while occurring at distant sites at either end of the C3 domains, is 
mutually exclusive [6, 28].  
 
The thermal lability of IgE has been recognised for a long time. Even before the 
recognition of IgE as an antibody, the loss of “reaginic” activity in atopic sera by 
heating to 56C was reported [29], and shortly after the discovery of the IgE antibody 
class, this unusually low thermal susceptibility compared with IgG (for which Tm 
values are typically ~72C), was confirmed [30].  
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Here we report two new crystal forms of Fc3-4 (at 2.26Å and 2.2Å resolution) 
together with one of the earlier forms now solved at the highest resolution yet 
reported (2.0Å) and IgE-Fc also solved at the highest resolution yet reported (1.75Å); 
new details concerning carbohydrate/protein interactions are revealed. We compare 
these with all previous structures, and propose a simplified, single-parameter 
descriptor for the quaternary structure of the C3 and C4 domains. An analysis of B-
factors for all IgE-Fc and Fc3-4 structures is also reported, and correlated with 
experimental data from differential scanning fluorimetry (DSF), which reveals the 
C3 domains to be responsible for the thermal sensitivity of IgE. 
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7 
2. Materials and methods 
 
2.1.  Protein preparation and crystallisation 
 
IgE-Fc and Fc3-4 were prepared as reported earlier [31, 6], and were a kind gift from 
Dr. A.J. Henry (UCB Pharma, Slough, UK). Crystals were grown at 18°C using the 
sitting drop vapour diffusion method. Fc3-4 crystals in the P1 and P21 ‘large’ form 
were grown in 0.1M SPG (succinic acid, sodium dihydrogen phosphate and glycine in 
the ratio 2:7:7) at pH 6.0 (Hampton Research) and 25% (w/v) PEG1500 using a 
reservoir volume of 70L and drops comprising 100nL protein solution (10mg/mL) 
and 100nL reservoir. The Fc3-4 P21 ‘small’ form was grown in 0.1M MES at pH 
5.5, 25% (w/v) PEG 4000 (Hampton Research) and 0.15M ammonium sulphate using 
a reservoir volume of 80μL and drops comprising 100nL protein solution (7.7mg/mL) 
and 200nL reservoir. IgE-Fc crystals were grown in 0.1M Tris HCl at pH 8.5 and 
25% (v/v) PEG 550 MME (Hampton Research), using a reservoir volume of 80µL 
and drops comprising 250nL protein solution (6mg/mL) and 250nL reservoir. 
 
Crystals were cryoprotected as follows:  Fc3-4 P1 crystals were cryoprotected in 
0.1M SPG at pH 4.4 and 30% (w/v) PEG 1500, Fc3-4 P21 ‘large’ crystals in 0.1M 
sodium di-hydrogen phosphate at pH 4.0 and 30% (w/v) PEG 3350, Fc3-4 P21 
‘small’ crystals in 25% (w/v) PEG 4000 and 18% (v/v) PEG 400, and IgE-Fc crystals 
in 0.1M Tris-HCl at pH 8.5, 25% (v/v) PEG 550 MME and 10% (v/v) PEG 400, 
before flash-cooling in liquid nitrogen.   
 
2.2.  Structure determination, model building and refinement 
 
Data were collected at the Diamond Light Source (Harwell, UK). For the Fc3-4 P1 
crystals (beamline I02), data were collected using an ADSC Q315r detector (250 
images, 1° oscillation, 0.7 s exposure, λ 0.9795Å). For the Fc3-4 P21 ‘large’ crystal 
form (beamline I04), data were collected using an ADSC Q315r detector (235 images, 
0.7° oscillation, 0.87 s exposure; λ 0.9763Å). For the Fc3-4 P21 ‘small’ crystal form 
(beamline I02) data were collected using a Pilatus 6M-F detector (1600 images, 0.2 
oscillation, 0.2 s exposure, λ 0.97949Å). For the IgE-Fc crystal (beamline I04-1), data 
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8 
were collected using a Pilatus 6M-F detector (1800 images, 0.2 oscillation, 0.2 s 
exposure, λ 0.92819Å). Data were integrated with DIALS using the Xia2 package 
[32] and scaled with AIMLESS [33] from the CCP4 suite [34]. 
 
The number of molecules in each asymmetric unit (Table 1) was correctly predicted 
using Matthews probability analysis [35, 32]. All structures were solved by molecular 
replacement with PHASER [37] using the Fc3-4 structures, PDB entries 3HA0, 
3H9Y and 3H9Z [18], as search models for the P1 and P21 ‘large’ and P21 ‘small’ 
structures, respectively. For the IgE-Fc structure, PDB entry 2WQR [5] was used as a 
search model. The Fc3-4 P21 ‘large’ structure is the same crystal form as 3H9Y, and 
the IgE-Fc structure is the same crystal form as 2WQR, but both structures represent 
an improvement in terms of resolution. Refinement was carried out in iterative cycles 
with PHENIX [38] using weight optimization, and alternated with manual model 
building using COOT [39]. Structure quality was assessed with MolProbity [40]. Data 
processing and refinement statistics for all structures are presented in Table 1. Figures 
were prepared with PyMOL (Version 1.8.2.1 Schrödinger, LLC) 
 
In the IgE-Fc structure, residues were built as follows: chain A 228-544; chain B 225-
545. In the Fc3-4 P21 ‘small’ structure: chain A 336-365, 370-424, 427-544; chain B 
336-362, 369-422, 429-544. In the Fc3-4 P21 ‘large’ structure: chain A 336-424, 
428-546; chain B 336-363, 369-545; chain C 335-362, 369-421, 428-544; chain D 
336-366, 369-422, 428-544. In the Fc3-4 P1 structure: chain A 339-360, 372-389, 
398-419, 430-544; chain B 338-362, 369-393, 398-421, 428-544; chain C 336-544; 
chain D 335-362, 369-421, 429-498, 503-544; chain E 336-362, 369-423, 425-454, 
457-544; chain F: 339-361, 372-376, 379-381, 383-389, 394-418, 431-454, 456-544. 
Carbohydrate was built at Asn394 as follows: IgE-Fc structure chain A 
GlcNAc2Man3; chain B GlcNAc2Man5. In the Fc3-4 P21 ‘small’ structure: chain A 
GlcNAc2Man3; chain B GlcNAc2Man3. In the Fc3-4 P21 ‘large’ structure: chain A 
GlcNAc2Man2; chain B GlcNAc2Man5; chain C GlcNAc1Man3; chain D GlcNAc 
2Man5. In the Fc3-4 P1 structure: chain A GlcNAc1Man3; chain B GlcNAc2Man3; 
chain C GlcNAc2Man3; chain D GlcNAc2Man5; chain E GlcNAc2Man3; chain F 
GlcNAc0Man3. For the quaternary structural comparisons, the angle defined by the 
three C atoms X337-X497-Y337 or Y337-Y497-X337 (where X and Y refer to two 
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paired chains) was measured using the PyMOL Molecular Graphics System (Version 
1.8.2.1 Schrödinger, LLC). NB: where residues 337 or 497 were not modelled in the 
structure (Fc3-4 P1 structure chains A and B, structure 5ANM chain A, B, C and D 
and structure 3H9Y chain A, B and C), the measurement was not taken.  
 
2.3.  B-factor analyses of structures 
 
All chains of the four new structures presented here, together with all published Fc3-
4 and IgE-Fc structures, were analysed. To compare B-factors derived from different 
structure determinations, each was normalised by division by the average B-factor for 
the whole C3-4 chain (for comparison of C3 and C4) or C3 domain (for 
comparison of the C4-distal region and C4-proximal region). The C3/C4 
boundary was defined as residues 437/438; the C4-distal region of C3 was defined 
as residues 336-339, 359-372, 387-400 and 419-431; the C4-proximal region of C3 
was defined as residues 340-358, 373-386, 401-418 and 432-437.  
    
2.4.  Differential scanning fluorimetry 
 
Thermal stability assays were carried out according to a published protocol [41] using 
the Stratagene Mx3005p RT-PCR instrument. Sypro orange was used as fluorescent 
dye (Life Technologies) with filters at 492nm (excitation) and 610nm (emission). The 
concentration for both proteins was 5M. Each sample was measured in duplicate for 
Fc3-4 and in triplicate for IgE-Fc. Positive controls were performed with lysozyme 
(data not shown) and negative controls as follows: protein with no Sypro orange, 
Sypro orange with buffer, and buffer alone (data not shown). Melting temperatures 
were taken as the maxima of the first derivative calculated using Graphpad Prism 
version 7 (Table 2). 
 
2.5 Mass spectrometry 
 
The two protein samples, either IgE-Fc or Fc3-4, were dialysed into a solution of 
H2O, 10% acetonitrile and 0.1% formic acid prior to mass spectrometric analyses. 
Samples at concentrations between 8μg/mL and 80μg/mL were directly infused at 
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25μL/minute into a Bruker MaXis ultrahigh-resolution electrospray ionization 
quadropole time-of-flight mass spectrometer. The multiple charge states were 
deconvoluted using the manufacturer's maximum entropy algorithm (Bruker 
Daltonics).  Due to glycosylation heterogeneity, a series of masses were observed 
with well-defined mass differences of 162 Da, corresponding to variations in the 
number of mannose residues present in the sample [12].  For IgE-Fc, the derived 
masses were consistent with intact protein with a single N-linked glycosylation site 
per chain, with two GlcNAc residues and 1-7 mannose residues.   For Fc3-4, the 
derived masses were consistent with intact protein with a single N-linked 
glycosylation site per chain, containing two GlcNAc residues and 5-9 mannose 
residues.  Both protein samples also show evidence of partial loss of their C-terminal 
lysine residue, a common modification observed in recombinantly expressed 
antibodies [42].   
3. Results and discussion  
3.1.  Overall structure  
The new crystal forms of Fc3-4, P1 and P21 ‘small’ contain three molecules (six 
chains) in the asymmetric unit (solved at 2.2Å resolution), and one molecule (two 
chains) in the asymmetric unit (solved at 2.26Å) respectively.  They therefore offer 
four additional and unique packing environments for analysis of the intrinsic 
flexibility of this molecule (Figs. 1A and 1C).  The other crystal form, P21 ‘large’, 
with two molecules (four chains) in the asymmetric unit, has been reported earlier 
[18] but is now solved at 2.0Å resolution, the highest yet reported for any Fc3-4 
structure (Fig. 1B). The IgE-Fc structure, space group P21212, with one molecule (two 
chains) in the asymmetric unit has been determined to 1.75Å resolution (Fig. 1D), 
which is the highest reported for this structure. The structure of the carbohydrate, 
disposition of domains compared with other IgE-Fc and Fc3-4 structures, and 
relative flexibility within and between domains, will be discussed in the following 
sections. 
 
3.2.   Conformation of the N-linked carbohydrate 
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A branched, bi- or tri-antennary, high-mannose type carbohydrate chain 
((GlcNAc)n(Man)n) is N-linked to Asn394 in each C3 domain, as seen in previous 
crystal structures of IgE-Fc and Fc3-4 at different resolutions, and with varying 
degrees of disorder. There is heterogeneity in the overall mannose content and in the 
length of the branches in any population of IgE-Fc or Fc3-4 molecules (Fig. 2) [12, 
13, 14, 15). Fig. 2C shows the various high-mannose carbohydrate structures seen in 
the four crystal structures reported. Ordered carbohydrate residues were modeled as 
follows: IgE-Fc structure, GlcNAc2Man3 (chain A) (Fig. 2Ciii) and GlcNAc2Man5 
(chain B) (Fig. 2Ci); Fc3-4 P21 ‘small’ structure, GlcNAc2Man3 (chains A and B) 
(Fig. 2Cii); Fc3-4 P21 ‘large’ structure, GlcNAc2Man5 (chains B and D) (Fig. 2Ci), 
GlcNAc2Man2 (chain A) (Fig. 2Civ) and GlcNAc1Man3 (chain C) (Fig. 2Cv); Fc3-4 
P1 structure, GlcNAc2Man3 (chains C and E) (Fig. 2Cii), GlcNAc2Man5 (chain D) 
(Fig. 2Ci), GlcNAc2Man3 (chain B) (Fig. 2Ciii), GlcNAc1Man3 (chain A) (Fig. 2Cv) 
and GlcNAc0Man3 (chain F) (Fig. 2Cvi). 
 
A remarkable feature of the carbohydrate attached to chain D in the Fc3-4 P21 
‘large’ crystal form and chain F in the Fc3-4 P1 crystal form is that while the 
terminal units are well defined, there is poor (or absent) electron density at a contour 
level of 1 in the 2FoFc map for the first GlcNAc (P21 ‘large’) or first two GlcNAc 
units (P1), as well as for the covalent connection between these and Asn394 (Figs. 3B 
and 3D). This covalent connection is well defined however in chain D of the Fc3-4 
P21 ‘large’ structure, and chain E of the Fc3-4 P1 structure (Figs. 3A and 3C). 
 
The terminal units make clearly defined contacts with residues of the C3 and C4 
domains. For example, in IgE-Fc chain B a terminal mannose residue, Man 952, 
forms a hydrogen bond with the main-chain of Arg342. Hydrogen bonds mediated by 
water molecules are also formed between: Man952 and Ser344, Ser341, Ile474 and 
Ser475; Man953 and Thr492 (Fig. 4A). In the Fc3-4 P21 ‘large’ structure chain D, a 
terminal mannose residue, Man949, forms hydrogen bonds with main-chain atoms of 
Arg342 and Ile474; Man950 forms hydrogen bonds with Thr492; Man947 forms 
hydrogen bonds with Gln494. Hydrogen bonds mediated by water molecules are also 
formed between: Man948 and Ser341, Thr357, Ile474 and Thr493; Man949 and 
Arg342, Asp347, Asp473, and Ser475; Man950 and Thr492 (Fig. 4B). With the 
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12 
exception of Man947-Gln494, these hydrogen bonds are not seen in the other chains, 
or in any of the previously published Fc3-4 or IgE-Fc structures.  
 
In IgG-Fc, complex-type carbohydrate chains are attached at the structurally 
homologous Asn297 in C2, but in IgG contact is made only with the C2 domains, 
and never C3. In IgE, the more extensive high-mannose structures have the 
capability of reaching the C4 domains, and the Fc3-4 P21 ‘large’ structure reported 
here shows how the terminal carbohydrate units can be stabilised and contribute to 
linking, non-covalently, the C3 and C4 domains in IgE, even when the Asn394 loop 
to which it is covalently connected is relatively disordered.   
 
3.3.   Quaternary structural comparisons 
 
In their earlier analysis of the quaternary structural variation in IgE-Fc and Fc3-4, 
Wurzburg and Jardetzky defined two motions of the C3 domains relative to each 
other, an “opening/closing” and a “swinging” [18]. The C4 domain pair is virtually 
identical in all structures and provides a reference point for comparing the disposition 
of the C3 domains. These authors defined two distance measurements: C of residue 
394 of one chain (X) to C497 of the other chain (Y) for the “opening/closing”, and 
C336(X) to C336(Y) for the “swinging”. These were displayed as a 2d plot [18]. 
As these are in fact one concerted movement, with more “closed” structures showing 
less “swing” and more “open” structure showing more “swing” we propose 
combining both components with a single measurement of the angle defined by 
C337(X)-C497(X)-C337(Y) (Fig. 5), using the descriptors “open” and “closed”. 
Residue 337 was selected as it is located within the C3 domain, away from the C2-
C3 domain linker which undergoes a conformational change when IgE-Fc unbends 
[23]. 
 
We have compared all available IgE-Fc and Fc3-4 structures (now 34 molecules, 
compared with only 10 in the earlier analysis [18]); the single parameter clearly 
describes the wide range of open and closed C3 conformations (Fig. 5). The 
complexes with FcRI, and IgE-Fc bound to the omalizumab Fab, are the most open, 
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13 
while those bound to CD23 and the numerous uncomplexed Fc3-4 structures show 
how they almost span the entire range from closed to the open conformation in the 
FcRI complex: none however is as open as that seen in the omalizumab Fab / IgE-Fc 
complex. In contrast to Fc3-4, there is to date only a single crystal form of 
uncomplexed IgE-Fc despite extensive crystallisation trials (authors’ unpublished 
observations). This may imply that the C2 domains stabilise, through extensive 
contact with one of the C3 domains, an intermediate quaternary structure (between 
open and closed) [17].  The recent structure of the complex between IgE-Fc and two 
anti-IgE aFab molecules unexpectedly revealed that the C2 domains can also adopt 
an extended, linear conformation with respect to the Fc3-4 region, with no C2/C3 
domain contact [23]. When this occurs, the C3 domains adopt a quaternary structure 
that is incompatible with FcRI binding; the quaternary structure lies between the two 
extremes (Fig. 5). A similar phenomenon was observed for Fc3-4 bound to another 
anti-IgE Fab, MEDI4212 [24]. The artificially constrained Fc3-4 structures and 
complexes with DARPin and omalizumab [20, 19, 25], are clearly more closed (Fig. 
5). The C3 domains in this Fc3-4 construct are, however, tethered by an artificial 
disulphide bond that prevents any relative movement. In contrast, IgE-Fc bound to 
omalizumab exhibits the most open conformation seen, and is also incompatible with 
FcRI binding [26]; IgE-Fc is partially bent in this complex. It is also clear from this 
comparison that despite the 26 independent chain conformations observed in free 
Fc3-4 (and the single uncomplexed IgE-Fc structure), none is sufficiently open to 
permit FcRI binding; engagement of receptor must occur at one sub-site before full 
opening occurs. In contrast, many of the free Fc3-4 structures adopt conformations 
that are receptive for CD23 binding. 
 
3.4.   Flexibility of the C3 domains 
 
The new structures show disorder in the loops and adjoining -strands of the region of 
C3 most distant from the C4 domains. (The two halves of the C3 domain will here 
be referred to as the C4-proximal and C4-distal regions; for definition by residue 
number, refer to Materials and methods). While this has been seen in other Fc3-4 
(and also some IgG-Fc structures [41]), it is particularly marked in the new Fc3-4 P1 
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form, and this prompted an analysis of the relative B-factors across all of the Fc3-4 
and IgE-Fc structures, comparing C3 with C4 (Fig. 6A&B), and also the C4-
proximal and C4-distal regions of C3 (Fig. 6C&D). In order to compare B-factors 
from structures refined with different protocols and at different resolutions, the values 
for each chain or domain were normalised by dividing by the average B-factor (refer 
to Materials and methods).  
 
The B-factor analysis revealed that the C3 domains showed greater intrinsic 
flexibility than the C4 domains in the unbound Fc3-4 and IgE-Fc structures, despite 
the range of different crystal packing environments (Fig. 6A). In the FcRI-bound, 
aFab-bound and omalizumab Fab-bound IgE-Fc structures, the opposite effect is 
seen, undoubtedly due to the stabilising effect of FcRI, aFab and omalizumab Fab 
binding to the C3 domains. In the CD23-bound, MEDI4212-bound and artificially 
constrained Fc3-4 crystal structures, B-factors for the C3 and C4 domains are 
similar (Fig. 6A).  
 
Comparison of B-factors within the C3 domain (Fig 6B) shows that the C4-distal 
region displays the greater degree of disorder or flexibility in virtually all of the 
structures, including IgE-Fc and also the Fc3-4/CD23 complexes. The C4 domains, 
through extensive interactions with C3, stabilise the C4-proximal regions of C3, 
but the C2 domains in IgE-Fc do not have the same effect upon the C4-distal region 
(Fig. 6A). In the FcRI-bound, the extended aFab-bound and the omalizumab Fab-
bound IgE-Fc structures, the C4-distal region of C3 is stabilised, unsurprisingly, 
since this is the location of the two receptor sub-sites, one in each C3, and the aFab 
binding site [4, 5]; the omalizumab Fab epitope is located on the exposed outer face 
of the C3 domain [26]. The pattern for MEDI4212-bound Fc3-4 is again different, 
but its epitope principally involves the C4-proximal region of C3. 
 
This flexibility of the C3 domains in the context of IgE-Fc and Fc3-4 and their 
stabilisation by FcRI-binding is consistent with the more extreme behaviour of the 
C3 domain when studied in isolation: alone it behaves as a partially folded “molten 
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globule” [7, 8, 9, 10], yet it can bind sFcRI [11, 7] and, in its presence, adopt a 
more folded structure [8,9]. 
 
3.5.   Differential stability of the IgE-Fc domains  
 
The thermally-induced unfolding of Fc3-4 and IgE-Fc in the presence of increasing 
concentrations of urea was measured by DSF (Fig. 7). The Fc3-4 data show a single 
unfolding event at all urea concentrations. The unfolding event occurs at 52C in the 
absence of urea, and at lower melting temperatures as the urea concentration is 
increased (Fig. 7, Table 2). This implies that the C3 and C4 domains unfold 
cooperatively. The IgE-Fc data however shows a two-state unfolding (Fig. 7), the first 
event, in the absence of urea, at 55C (Tm1) and the second at 64C (Tm2). The latter 
is taken to be the unfolding of the C2 domains, occurring after that of C3 and C4. 
Both Tm1 and Tm2 decrease with increasing urea concentration (Fig. 7, Table 2).  For 
Fc3-4, and also for these domains within IgE-Fc, 4M urea causes complete unfolding 
in the absence of heating, whereas >6M urea is required to achieve this for the C2 
domains. 
The intensity of the signals from Fc3-4 are consistently smaller than those from IgE-
Fc (at the same concentration), which may be due to differences in the aggregation 
properties of the two proteins as denaturation occurs. Aggregation reduces the 
hydrophobic surface area to which Sypro-orange molecules can bind, thus reducing 
the signal. The C3 domains, and in particular the N-terminal regions, are more 
flexible (as seen in crystal structures) and perhaps inherently more prone to unfolding 
in Fc3-4 compared with IgE-Fc, thus promoting aggregation of the former. However, 
as seen in the B-factor analysis (Fig. 6A), the stabilising effect of the (C2)2 domain 
pair upon the Fc3-4 region is relatively modest, since the Tm and Tm1 values for 
Fc3-4 and IgE-Fc respectively are very similar under all urea conditions (Table 2).  
4.  Conclusions 
The C3 domains are central to the function of IgE since they contain the receptor-
binding sites for both FcRI and CD23. These two sites are located at opposite ends 
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of the C3 domain, yet their binding is mutually incompatible [6, 28]. Allosteric 
communication between these two sites clearly involves quaternary structural changes 
in IgE-Fc and Fc3-4 domains, predominantly in the relative disposition of the C3 
domains [6, 28]. However, the C3 domain has been identified as an outlier according 
to various measures of folding and stability [10], and it may be that this unique 
behaviour is required in order to transmit the allosteric signal. The three new Fc3-4 
crystal structures reported here contribute to understanding both the intrinsic 
flexibility of the C3 domains and their quaternary structure, and we have now 
compared all of the (34) available IgE-Fc and Fc3-4 structures. This highlights the 
more extreme conformational variation in C3 than was seen in an earlier analysis 
based upon the far fewer structures then available [18]. Furthermore, the enhanced 
resolution for two of the structures reported here provides new detail concerning the 
ordered regions of the N-linked carbohydrate that is attached to this intrinsically 
flexible domain. 
 
Analysis of the B-factors from all the published crystal structures together with the 
new structures presented here confirms the enhanced intrinsic flexibility of the C3 
domains and demonstrates that this is most pronounced in their C4-distal regions. 
The ability to average over so many different structures in different crystal forms, 
overcomes any local effects of crystal packing constraints. The C3 domains are 
stabilised by FcRI binding (Fig. 6), consistent with the results of experiments 
conducted with isolated C3 domains binding to sFcRI [8, 9] and with thermal 
stability data reported for IgE-Fc with and without sFcRI [44].  
 
The thermal stability data that we present here implicate the C3 domains as the most 
susceptible to denaturation within IgE-Fc. The thermal lability of IgE has been 
recognised for a long time. Even before the recognition of IgE as an antibody, the loss 
of “reaginic” activity in atopic sera by heating to 56C was reported [29], and shortly 
after the discovery of the IgE antibody class, this unusual thermal susceptibility 
compared with IgG (for which Tm values are typically ~72C), was confirmed [30]. 
Furthermore, on the basis of circular dichroism spectroscopy and retention or loss of 
antigenic determinants as a function of temperature, Dorrington and Bennich were 
able to write that “the irreversible changes seen with intact IgE result from structural 
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changes in that portion of chain C-terminal to Fc’’- [their terminology for the C2 
domains]”, i.e. in the C3-4 domains [30]. We show here that IgE-Fc unfolds in a 
two-step process, the first involving the Fc3-4 region with Tm values similar to that 
of intact IgE, and the second involving the C2 domains. Since the Tm1 and Tm values 
for IgE-Fc and Fc3-4 respectively are very similar, the C2 domains have only a 
marginal influence on the thermal stability of the C3 domains. 
 
In IgG-Fc, glycosylation of the complex type, N-linked at the structurally homologous 
Asn297 in each C2, contributes to the thermal stability of this domain, and the two 
domains have distinct Tm values: glycosylated, 71C and 82C for C2 and C3 
respectively; fully deglycosylated, 66C and 82C [45]. In contrast, Fc3-4 unfolds 
cooperatively at the much lower temperature of 52C even when fully glycosylated 
(Fig. 7 and Table 2). Deglycosylation of Fc3-4 further reduces the Tm by 4C [46]. 
The inability of the high-mannose carbohydrate to stabilise the C3 domain is 
consistent not only with its intrinsic lability, but also with the remarkable observation 
that at the point of covalent connection to Asn394 in C3, in chain C of the Fc3-4 
P21 “large” form and chain F of the P1 form, the flexibility and/or disorder is so great 
that there is no visible electron density (Fig. 3B&D); this is despite the fact that, as 
seen most clearly in the structure reported here, well-ordered carbohydrate units make 
contact with C4 (Fig. 4). In IgG-Fc, no carbohydrate contact is ever made with the 
C3 domains. This difference between IgG and IgE is also reflected in the functional 
requirement for Fc glycosylation. Whereas substantially reduced glycosylation 
compromises IgG-Fc receptor-mediated effector functions [47], glycosylation at 
Asn394, while required for folding and secretion of IgE in vitro and in vivo [15], is 
not essential for either FcRI or CD23 binding, since refolded IgE-Fc lacking 
carbohydrate altogether has native-like affinity for both receptors [48, 49, 50, 51]. 
The relationship between glycosylation, structure and function in IgE is thus very 
different to IgG, and appears to be yet another unique feature of this class of antibody. 
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Coordinates and structure factors have been deposited in the Protein Data Bank with 
accession numbers:  Fc3-4 P1, PDB ID: 5MOI; Fc3-4 P21 ‘small’, PDB ID: 5MOJ; 
Fc3-4 P21 ‘large’, PDB ID: 5MOK; IgE-Fc, PDB ID: 5MOL. 
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Figure Legends 
 
Fig. 1. Contents of the asymmetric units of the four crystal forms. Fc3-4 
structures in the P1, P21 ‘large’ and P21 ‘small’ crystal forms and IgE-Fc structure in 
the P21212 crystal form with 3, 2, 1 and 1 molecule(s) in each asymmetric unit, 
respectively. (A) Fc3-4 P1 crystal form: chain A (cyan), chain B (green), chain C 
(magenta), chain D (yellow), chain E (salmon) and chain F (grey). (B) Fc3-4 P21 
‘large’ crystal form: chain A (cyan), chain B (green), chain C (magenta) and chain D 
(yellow). (C) Fc3-4 P21 ‘small’ crystal form: chain A (cyan) and chain B (green). (D) 
IgE-Fc P21212 crystal form: chain A (cyan) and chain B (green). Carbohydrate is 
displayed as sticks and modelled in all chains.  
 
Fig. 2. Carbohydrate structures in the four crystal forms. (A) Mass spectrometry 
trace showing carbohydrate present in IgE-Fc. The molecular mass of the polypeptide 
dimer is 72 604 Da, and with two N-acetylglucosamine (GlcNac) residues per chain is 
73 416 Da. The first peak in the spectrum corresponds to one additional mannose 
(Man) residue in each chain. (B) Mass spectrometry trace showing carbohydrate 
present in Fc3-4. The molecular mass of the polypeptide dimer is 49 756 Da, and 
with two GlcNac residues per chain is 50 568 Da. (C) Blue squares represent GlcNAc 
and green circles, Man units. i) Shows the arrangement of the high-mannose N-linked 
carbohydrate modelled in IgE-Fc chain B, Fc3-4 P21 ‘large’ chains B and D, and 
Fc3-4 P1 chain D. ii) Shows the carbohydrate modelled in Fc3-4 P21 ‘small’ chains 
A and B, and in Fc3-4 P1 chains C and E. iii) Shows the carbohydrate modelled in 
IgE-Fc chain A and Fc3-4 P1 chain B. iv) Shows the carbohydrate modelled in Fc3-
4 P21 ‘large’ chain A. v) Shows the carbohydrate modelled in Fc3-4 P21 ‘large’ 
chain C and Fc3-4 P1 chain A. vi) Shows the carbohydrate modelled in Fc3-4 P1 
chain F.  
 
Fig. 3. Electron density for carbohydrate at Asn394 in chains E and F of the 
Fc3-4 P1 crystal form, and chains C and D of the Fc3-4 P21 ‘large’ crystal 
form. (A) Chain E of the Fc3-4 P1 form: the covalent connection between Asn394 
and GlcNAc has well defined density. (B) Chain F of the Fc3-4 P1 form: Asn394 has 
poorly defined density and the two GlcNAc units are missing. (C) Chain C of the 
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Fc3-4 P21 ‘large’ form: the covalent connection between Asn394 and GlcNAc has 
well defined density. (D) Chain D of the P21 ‘large’ form: Asn394 has poorly defined 
density and the first GlcNAc unit is missing. Polypeptide is shown as black lines and 
carbohydrate is coloured by atom type. The electron density is represented by grey 
mesh (2Fo-Fc map at a contour level of 1). 
 
Fig. 4. Contacts between carbohydrate and the C3 and C4 domains in the IgE-
Fc crystal structure chain B and the Fc3-4 P21 ‘large’ crystal form chain D. (A) 
IgE-Fc crystal structure chain B showing interactions between: Ser341, a water 
molecule and Man952; Arg342 and Man952; Ser 344, a water molecule and Man952; 
Ser475, a water molecule and Man952; Ile474, a water molecule and Man952; a 
polyethylene glycol molecule (PEG4), a water molecule and Man953; Thr492, a 
water molecule and Man953. (B) Fc3-4 P21 ‘large’ crystal form chain D showing 
interactions between: Thr357, three water molecules and Man948; Ser341, a water 
molecule and Man948; Arg342, a water molecule and Man949; Arg342 and Man949; 
Asp347, two water molecules and Man949; Asp473 a water molecule and Man949; 
Ser475 a water molecule and Man949; Ile474 and Man949; Ile474, three water 
molecules and Man948; Thr492 and Man950; Thr492, a water molecule and Man950; 
Thr493, two water molecules and Man948; Gln494 and Man947. Hydrogen bonds are 
shown as grey dotted lines and the black crosses are ordered, bridging water 
molecules. Carbohydrate residues (shown as sticks) are coloured by atom type, and 
the C3 and C4 domains are coloured pink and blue, respectively. 
 
Fig. 5. Quaternary structural differences in the C3 domains of Fc3-4 and IgE-
Fc. (A) These are defined by the angle X337-X497-Y337 or Y337-Y497-X337, 
where X is one chain and Y is the paired chain. Plotted are values for CD23-bound 
structures (blue), FcεRI-bound IgE-Fc and Fc3-4 structures (red), Fcε3-4 structures, 
including P1 and P21 ‘large’ and ‘small’ structures reported here (lilac), IgE-Fc, 
including the structure reported here (green), aFab-bound IgE-Fc (orange), 
MEDI4212-bound Fc3-4 (cyan) artificially constrained Fc3-4 structures (pink), 
omalizumab-bound IgE-Fc (salmon). (B) Top and front views of Fc3-4 indicate 
residues 337 (in blue) and 497 (in red). The structure illustrated is that of the P21 
‘small’ crystal form. 
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Fig. 6. B-factor analysis of Fcε3-4 between domains and within C3. (A) Plot of 
normalised B-factors (refer Materials and methods) for C3 and C4 domains: CD23-
bound structures (blue), FcRI-bound structures (red), Fc3-4 structures (lilac), IgE-
Fc structure (teal), aFab-bound (extended) IgE-Fc (pink), MEDI4212-bound Fc3-4 
(orange), artificially constrained Fc3-4 structures (black) and omalizumab-bound 
IgE-Fc (dark pink). (B) Indicates the C3 (red) and C4 (blue) domains. (C) Graph of 
normalised B-factors for C4-distal and C4-proximal regions of the Cε3 domains: 
colours as for panel A. (D) Indicates the C4-distal (red) and C4-proximal (blue) 
regions of the Cε3 domains. The C4 domains are coloured grey. 
 
Fig. 7. Thermal stability of IgE-Fc and Fc3-4. The unfolding of IgE-Fc and Fc3-4 
as a function of temperature and urea concentration, measured by DSF, are compared. 
(A) 0M urea. (B) 1M urea. (C) 2M urea. (D) 3M urea. (E) 4M urea. Melting 
temperatures reported in Table 2 were determined from the first derivative plots 
calculated from these curves.   
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Fig. 4  
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Fig. 5  
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Fig. 6  
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Table 1. Data processing and refinement statistics 
 
Data processing Fcε3-4 (1) Fε3-4 (2) Fcε3-4 (3) IgE-Fc 
Structure name P 1 P 21 “large” P 21 “small” IgE-Fc 
No. of molecules in 
asymmetric unit 
3 2 1 1 
Space group P 1 P 1 21 1 P 1 21 1 P 21 21 2 
Unit cell dimensions 
(Å) 
a = 47.67 
b = 90.30 
c = 92.91 
 = 114.41° 
 = 90.63° 
 = 96.10° 
a = 66.48 
b = 100.36 
c = 77.86 
 = 97.35° 
a = 46.53 
b = 104.07 
c = 52.94 
 = 101.54° 
a = 130.67 
b = 75.78 
c = 79.82 
Resolution (Å): 
Overall (outer shell) 
81.61-2.20 
(2.25-2.20) 
100.36-2.00 
(2.05-2.00) 
51.87-2.26  
(2.33-2.26) 
79.82-1.75 
(1.80-1.75) 
Completeness (%)
a 98.9 (97.0) 100 (100) 99.9 (99.9) 99.9 (99.8) 
Multiplicity
a 5.7 (3.8) 14 (8.8) 4.1 (4.2) 13.1 (11.4) 
Mean ((I)/σ(I))a 7.5 (2.0) 14 (1.6) 5.9 (2.0) 14.0 (1.3) 
Rmerge
a 0.13 (1.103) 0.291 (2.218) 0.130 (1.834) 0.098 (1.982) 
Rpim
a 0.085 (0.899) 0.069 (1.143) 0.069 (1.000) 0.028 (0.607) 
CC1/2
a 0.997 (0.656) 0.995 (0.651) 0.993 (0.362) 0.999 (0.495) 
Wilson B-factor (Å
2
) 43.66 32.92 46.51 25.10 
Refinement     
Rwork / Rfree (%)
b 21.34 / 23.36 20.24 / 22.60 20.15 / 23.56 19.73 / 23.23 
No. of reflections 60 090 68 373 23 108 80 159 
RMSD:     
Bond lengths (Å) 0.003 0.003 0.006 0.009 
Bond angles (°) 0.591 0.619 0.767 0.944 
Coordinate error (Å) 0.27 0.25 0.30 0.27 
No. of atoms:     
Protein 8 732 6 358 2 986 4 933 
Carbohydrate 346 263 122 144 
Solvent 213 519 37 601 
Other 73c 33d 50e 72f 
Ramachandran plot:     
Favoured (%) 98.09 98.28 97.42 98.00 
Allowed (%) 99.82 100 100 100 
 
a 
Values in parentheses are for the highest resolution shell 
b 
Rfree set comprises 5% of reflections 
c
 ethylene glycol, polyethylene glycol, phosphate 
d
 ethylene glycol, polyethylene glycol 
e
 ethylene glycol, polyethylene glycol, sulphate 
f
 ethylene glycol, polyethylene glycol 
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Table 2. Melting temperatures for Fc3-4 and IgE-Fc  
 
Urea Concentration (M) Tm (Fc3-4) (C) Tm1 (IgE-Fc) (C) Tm2 (IgE-Fc) (C) 
0 52 55 64 
1 48 50 63 
2 47 45 57 
3 39 39 53 
4 - - 49 
5 - - 46 
6 - - 42 
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